Compounds > rrx-001
Page last updated: 2024-11-12

rrx-001

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

RRx-001: has antineoplastic activity; structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID15950826
CHEMBL ID3526802
SCHEMBL ID2249018
MeSH IDM0580411

Synonyms (33)

Synonym
S8405
rrx 001 [who-dd]
radiosensitizer rrx-001
abdnaz
n-(bromoacetyl)-3,3-dinitroazetidine
2-bromo-1-(3,3-dinitroazetidin-1-yl)ethan-1-one
rrx-001
unii-7rpw6su9sc
925206-65-1
2-bromo-1-(3,3-dinitroazetidin-1-yl)ethanone
7rpw6su9sc ,
ethanone, 2-bromo-1-(3,3-dinitro-1-azetidinyl)-
HY-16438
CS-5286
SCHEMBL2249018
AC-32908
CHEMBL3526802
rrx 001
1-bromoacetyl-3,3-dinitroazetidine
P15978
AS-53015
DB12060
rrx001
BCP19228
mfcd25976849
CCG-267126
EX-A2006
Q27268765
AKOS037644389
2-bromo-1-(3,3-dinitro-1-azetidinyl)ethanone
SY100127
BR164811
c5h6brn3o5

Research Excerpts

Toxicity

The primary objective was to assess safety, tolerability, and dose-limiting toxic effects of RRx-001. The goal was to determine single-dose pharmacokinetics, and to identify a recommended dose for phase 2 trials.

ExcerptReferenceRelevance
" The primary objective was to assess safety, tolerability, and dose-limiting toxic effects of RRx-001, to determine single-dose pharmacokinetics, and to identify a recommended dose for phase 2 trials."( Safety and activity of RRx-001 in patients with advanced cancer: a first-in-human, open-label, dose-escalation phase 1 study.
Abrouk, NED; Burris, HA; Cabrales, P; Carter, CA; Fanger, GR; Fitch, WL; Infante, JR; Kim, MM; Knox, SJ; Korn, R; Lao, CD; Ning, S; Oronsky, A; Oronsky, B; Peehl, DM; Reid, T; Scicinski, J; Scribner, CL; Stirn, M; Taylor, MJ, 2015)		0.95
" Pain at the injection site, mostly grade 1 and grade 2, was the most common adverse event related to treatment, experienced by 21 (84%) patients."( Safety and activity of RRx-001 in patients with advanced cancer: a first-in-human, open-label, dose-escalation phase 1 study.
Abrouk, NED; Burris, HA; Cabrales, P; Carter, CA; Fanger, GR; Fitch, WL; Infante, JR; Kim, MM; Knox, SJ; Korn, R; Lao, CD; Ning, S; Oronsky, A; Oronsky, B; Peehl, DM; Reid, T; Scicinski, J; Scribner, CL; Stirn, M; Taylor, MJ, 2015)		0.73
"RRx-001 is a well-tolerated novel compound without clinically significant toxic effects at the tested doses."( Safety and activity of RRx-001 in patients with advanced cancer: a first-in-human, open-label, dose-escalation phase 1 study.
Abrouk, NED; Burris, HA; Cabrales, P; Carter, CA; Fanger, GR; Fitch, WL; Infante, JR; Kim, MM; Knox, SJ; Korn, R; Lao, CD; Ning, S; Oronsky, A; Oronsky, B; Peehl, DM; Reid, T; Scicinski, J; Scribner, CL; Stirn, M; Taylor, MJ, 2015)		2.17
" RRx-001 is a minimally toxic small molecule with a distinct chemical structure and mechanism of action."( Discovery of RRx-001, a Myc and CD47 Downregulating Small Molecule with Tumor Targeted Cytotoxicity and Healthy Tissue Cytoprotective Properties in Clinical Development.
Abrouk, N; Cabrales, P; Cannizzo, L; Caroen, S; Guo, X; Lybeck, M; Oronsky, A; Oronsky, B; Reid, TR; Sher, D; Wang, X; Wardle, B, 2021)		1.9
" There were no severe adverse events attributed to the study drug."( PREVLAR: Phase 2a Randomized Trial to Assess the Safety and Efficacy of RRx-001 in the Attenuation of Oral Mucositis in Patients Receiving Head and Neck Chemoradiotherapy.
Abrouk, N; Bar-Ad, V; Biagioli, M; Blakaj, DM; Bonomi, M; Caroen, S; Colvett, K; Goyal, S; Kabarriti, R; Muzyka, B; Niermann, K; Oronsky, B; Reid, T; Sher, DJ; Sonis, S; Takiar, V, 2023)		1.14

Dosage Studied

ExcerptRelevanceReference
" U87 tumors showed an absence of blood flow over large areas of treated tumors after dosing with RRx-001."( RRx-001, an epigenetic-based radio- and chemosensitizer, has vascular normalizing effects on SCCVII and U87 tumors.
Cabrales, P; Minchinton, A; Oronsky, B; Scicinski, J, 2016)		2.09
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (80)

Assay IDTitleYearJournalArticle
AID1220447Binding affinity to monkey hemoglobin assessed as protein bound compound level at 20 uM2012Drug metabolism and disposition: the biological fate of chemicals, Sep, Volume: 40, Issue:9
Preclinical evaluation of the metabolism and disposition of RRx-001, a novel investigative anticancer agent.
AID1220450Drug metabolism assessed as [(S)-2-amino-5-(((R)-1-((carboxymethyl)amino)-3-((2-(3-(hydroxyimino)azetidin-1-yl)-2-oxoethyl)thio)-1-oxopropan-2-yl)amino)-5-oxopentanoic acid] formation after 1 hr in presence of excess reduced GSH at pH 7.8 by LC-MS/MS meth2012Drug metabolism and disposition: the biological fate of chemicals, Sep, Volume: 40, Issue:9
Preclinical evaluation of the metabolism and disposition of RRx-001, a novel investigative anticancer agent.
AID1220395Drug metabolism in human whole blood assessed as [(S)-2-amino-5-(((R)-1-((carboxymethyl)amino)-3-((2-(3,3-dinitroazetidin-1-yl)-2-oxoethyl)thio)-1-oxopropan-2-yl)amino)-5-oxopentanoic acid] formation at 20 uM by LC-MS/MS method2012Drug metabolism and disposition: the biological fate of chemicals, Sep, Volume: 40, Issue:9
Preclinical evaluation of the metabolism and disposition of RRx-001, a novel investigative anticancer agent.
AID1220431Drug excretion in Wistar Hanover rat urine at 10 mg/kg, iv administered as single dose after 0 to 8 hrs2012Drug metabolism and disposition: the biological fate of chemicals, Sep, Volume: 40, Issue:9
Preclinical evaluation of the metabolism and disposition of RRx-001, a novel investigative anticancer agent.
AID1220400Drug metabolism in rat whole blood assessed as [(S)-2-amino-5-(((R)-1-((carboxymethyl)amino)-3-((2-(3-nitroazetidin-1-yl)-2-oxoethyl)thio)-1-oxopropan-2-yl)amino)-5-oxopentanoic acid] formation at 20 uM by LC-MS/MS method2012Drug metabolism and disposition: the biological fate of chemicals, Sep, Volume: 40, Issue:9
Preclinical evaluation of the metabolism and disposition of RRx-001, a novel investigative anticancer agent.
AID1220404Drug metabolism in rat whole blood assessed as [(R)-2-(2-amino-3-((2-(3,3-dinitroazetidin-1-yl)-2-oxoethyl)thio)propanamido)acetic acid] formation at 20 uM by LC-MS/MS method2012Drug metabolism and disposition: the biological fate of chemicals, Sep, Volume: 40, Issue:9
Preclinical evaluation of the metabolism and disposition of RRx-001, a novel investigative anticancer agent.
AID1814607Antiproliferative activity against human IMR-32 cells assessed as cell growth inhibition by CCK8 assay2021Journal of medicinal chemistry, 06-10, Volume: 64, Issue:11
Discovery of RRx-001, a Myc and CD47 Downregulating Small Molecule with Tumor Targeted Cytotoxicity and Healthy Tissue Cytoprotective Properties in Clinical Development.
AID1220419Binding affinity to dog hemoglobin assessed as protein bound compound level at 20 uM2012Drug metabolism and disposition: the biological fate of chemicals, Sep, Volume: 40, Issue:9
Preclinical evaluation of the metabolism and disposition of RRx-001, a novel investigative anticancer agent.
AID1220435Drug level in Wistar Hanover rat blood at 10 mg/kg, iv administered as single dose after 168 hrs relative to total radioactivity2012Drug metabolism and disposition: the biological fate of chemicals, Sep, Volume: 40, Issue:9
Preclinical evaluation of the metabolism and disposition of RRx-001, a novel investigative anticancer agent.
AID1220433Ratio of drug level in blood to plasma in Wistar Hanover rat at 10 mg/kg, iv administered as single dose after 0.083 hrs2012Drug metabolism and disposition: the biological fate of chemicals, Sep, Volume: 40, Issue:9
Preclinical evaluation of the metabolism and disposition of RRx-001, a novel investigative anticancer agent.
AID1220392Retention time in rat whole blood in presence of 0.1% formic acid in water at 20 uM by LC-MS/MS method2012Drug metabolism and disposition: the biological fate of chemicals, Sep, Volume: 40, Issue:9
Preclinical evaluation of the metabolism and disposition of RRx-001, a novel investigative anticancer agent.
AID1220390Retention time in human whole blood at 20 uM by LC-MS/MS method2012Drug metabolism and disposition: the biological fate of chemicals, Sep, Volume: 40, Issue:9
Preclinical evaluation of the metabolism and disposition of RRx-001, a novel investigative anticancer agent.
AID1220401Drug metabolism in human whole blood assessed as [(R)-2-amino-3-((2-(3-nitroazetidin-1-yl)-2-oxoethyl)thio)propanoic acid] formation at 20 uM by LC-MS/MS method2012Drug metabolism and disposition: the biological fate of chemicals, Sep, Volume: 40, Issue:9
Preclinical evaluation of the metabolism and disposition of RRx-001, a novel investigative anticancer agent.
AID1220448Binding affinity to human hemoglobin assessed as protein bound compound level at 20 uM2012Drug metabolism and disposition: the biological fate of chemicals, Sep, Volume: 40, Issue:9
Preclinical evaluation of the metabolism and disposition of RRx-001, a novel investigative anticancer agent.
AID1220430Drug excretion in Wistar Hanover rat urine at 10 mg/kg, iv administered as single dose after 168 hrs2012Drug metabolism and disposition: the biological fate of chemicals, Sep, Volume: 40, Issue:9
Preclinical evaluation of the metabolism and disposition of RRx-001, a novel investigative anticancer agent.
AID1220449Retention time in rat whole blood at 20 uM by LC-MS/MS method2012Drug metabolism and disposition: the biological fate of chemicals, Sep, Volume: 40, Issue:9
Preclinical evaluation of the metabolism and disposition of RRx-001, a novel investigative anticancer agent.
AID1220420Ratio of drug level in dog blood to dog plasma at 20 uM after 30 mins2012Drug metabolism and disposition: the biological fate of chemicals, Sep, Volume: 40, Issue:9
Preclinical evaluation of the metabolism and disposition of RRx-001, a novel investigative anticancer agent.
AID1814599Antiproliferative activity against human PANC-1 cells assessed as cell growth inhibition by CCK8 assay2021Journal of medicinal chemistry, 06-10, Volume: 64, Issue:11
Discovery of RRx-001, a Myc and CD47 Downregulating Small Molecule with Tumor Targeted Cytotoxicity and Healthy Tissue Cytoprotective Properties in Clinical Development.
AID1220391Retention time in human whole blood in presence of 0.1% formic acid in water at 20 uM by LC-MS/MS method2012Drug metabolism and disposition: the biological fate of chemicals, Sep, Volume: 40, Issue:9
Preclinical evaluation of the metabolism and disposition of RRx-001, a novel investigative anticancer agent.
AID1220437Drug level in Wistar Hanover rat stomach at 10 mg/kg, iv administered as single dose after 24 hrs2012Drug metabolism and disposition: the biological fate of chemicals, Sep, Volume: 40, Issue:9
Preclinical evaluation of the metabolism and disposition of RRx-001, a novel investigative anticancer agent.
AID1220399Drug metabolism in human whole blood assessed as [(S)-2-amino-5-(((R)-1-((carboxymethyl)amino)-3-((2-(3-nitroazetidin-1-yl)-2-oxoethyl)thio)-1-oxopropan-2-yl)amino)-5-oxopentanoic acid] formation at 20 uM by LC-MS/MS method2012Drug metabolism and disposition: the biological fate of chemicals, Sep, Volume: 40, Issue:9
Preclinical evaluation of the metabolism and disposition of RRx-001, a novel investigative anticancer agent.
AID1220425AUC (0 to t) in Wistar Hanover rat plasma at 10 mg/kg, iv administered as single dose2012Drug metabolism and disposition: the biological fate of chemicals, Sep, Volume: 40, Issue:9
Preclinical evaluation of the metabolism and disposition of RRx-001, a novel investigative anticancer agent.
AID1220427Volume of distribution in Wistar Hanover rat plasma at 10 mg/kg, iv administered as single dose2012Drug metabolism and disposition: the biological fate of chemicals, Sep, Volume: 40, Issue:9
Preclinical evaluation of the metabolism and disposition of RRx-001, a novel investigative anticancer agent.
AID1220406Drug metabolism in rat whole blood assessed as [(S)-2-amino-5-(((R)-1-((carboxymethyl)amino)-1-oxo-3-((2-oxo-2-(3-oxoazetidin-1-yl)ethyl)thio)propan-2-yl)amino)-5-oxopentanoic acid] formation at 20 uM by LC-MS/MS method2012Drug metabolism and disposition: the biological fate of chemicals, Sep, Volume: 40, Issue:9
Preclinical evaluation of the metabolism and disposition of RRx-001, a novel investigative anticancer agent.
AID1220414Binding affinity to rat hemoglobin assessed as protein bound compound level at 1 uM2012Drug metabolism and disposition: the biological fate of chemicals, Sep, Volume: 40, Issue:9
Preclinical evaluation of the metabolism and disposition of RRx-001, a novel investigative anticancer agent.
AID1220412Ratio of drug level in monkey blood to monkey plasma at 20 uM after 30 mins2012Drug metabolism and disposition: the biological fate of chemicals, Sep, Volume: 40, Issue:9
Preclinical evaluation of the metabolism and disposition of RRx-001, a novel investigative anticancer agent.
AID1882259Cytotoxicity against human multiple myeloma cells by WST-1 assay2022European journal of medicinal chemistry, Feb-05, Volume: 229A review on the treatment of multiple myeloma with small molecular agents in the past five years.
AID1220440Stability in water2012Drug metabolism and disposition: the biological fate of chemicals, Sep, Volume: 40, Issue:9
Preclinical evaluation of the metabolism and disposition of RRx-001, a novel investigative anticancer agent.
AID1814595Antitumor activity against mouse SCC-7 cells implanted in C3H mouse assessed as tumor growth time at 12 mg/kg, ip treated every other day 3 times in total (Rvb = 2.8 +/- 0.6 day)2021Journal of medicinal chemistry, 06-10, Volume: 64, Issue:11
Discovery of RRx-001, a Myc and CD47 Downregulating Small Molecule with Tumor Targeted Cytotoxicity and Healthy Tissue Cytoprotective Properties in Clinical Development.
AID1220429Drug excretion in Wistar Hanover rat feces at 10 mg/kg, iv administered as single dose measured on day 12012Drug metabolism and disposition: the biological fate of chemicals, Sep, Volume: 40, Issue:9
Preclinical evaluation of the metabolism and disposition of RRx-001, a novel investigative anticancer agent.
AID1220421Half life in Wistar Hanover rat blood at 10 mg/kg, iv administered as single dose2012Drug metabolism and disposition: the biological fate of chemicals, Sep, Volume: 40, Issue:9
Preclinical evaluation of the metabolism and disposition of RRx-001, a novel investigative anticancer agent.
AID1220451Drug metabolism assessed as [(S)-2-amino-5-(((R)-1-((carboxymethyl)amino)-1-oxo-3-((2-oxo-2-(3-oxoazetidin-1-yl)ethyl)thio)propan-2-yl)amino)-5-oxopentanoic acid] formation after 1 hr in presence of excess reduced GSH at pH 7.8 by LC-MS/MS method2012Drug metabolism and disposition: the biological fate of chemicals, Sep, Volume: 40, Issue:9
Preclinical evaluation of the metabolism and disposition of RRx-001, a novel investigative anticancer agent.
AID1220403Drug metabolism in human whole blood assessed as [(R)-2-(2-amino-3-((2-(3,3-dinitroazetidin-1-yl)-2-oxoethyl)thio)propanamido)acetic acid] formation at 20 uM by LC-MS/MS method2012Drug metabolism and disposition: the biological fate of chemicals, Sep, Volume: 40, Issue:9
Preclinical evaluation of the metabolism and disposition of RRx-001, a novel investigative anticancer agent.
AID1220405Drug metabolism in human whole blood assessed as [(S)-2-amino-5-(((R)-1-((carboxymethyl)amino)-1-oxo-3-((2-oxo-2-(3-oxoazetidin-1-yl)ethyl)thio)propan-2-yl)amino)-5-oxopentanoic acid] formation at 20 uM by LC-MS/MS method2012Drug metabolism and disposition: the biological fate of chemicals, Sep, Volume: 40, Issue:9
Preclinical evaluation of the metabolism and disposition of RRx-001, a novel investigative anticancer agent.
AID1814597Antiproliferative activity against mouse SCC-7 cells assessed as cell growth inhibition by CCK8 assay2021Journal of medicinal chemistry, 06-10, Volume: 64, Issue:11
Discovery of RRx-001, a Myc and CD47 Downregulating Small Molecule with Tumor Targeted Cytotoxicity and Healthy Tissue Cytoprotective Properties in Clinical Development.
AID1220434Drug excretion in Wistar Hanover rat feces at 10 mg/kg, iv administered as single dose measured on day 72012Drug metabolism and disposition: the biological fate of chemicals, Sep, Volume: 40, Issue:9
Preclinical evaluation of the metabolism and disposition of RRx-001, a novel investigative anticancer agent.
AID1814603Antiproliferative activity against human HT-29 cells assessed as cell growth inhibition by CCK8 assay2021Journal of medicinal chemistry, 06-10, Volume: 64, Issue:11
Discovery of RRx-001, a Myc and CD47 Downregulating Small Molecule with Tumor Targeted Cytotoxicity and Healthy Tissue Cytoprotective Properties in Clinical Development.
AID1220424Volume of distribution in Wistar Hanover rat blood at 10 mg/kg, iv administered as single dose2012Drug metabolism and disposition: the biological fate of chemicals, Sep, Volume: 40, Issue:9
Preclinical evaluation of the metabolism and disposition of RRx-001, a novel investigative anticancer agent.
AID1814602Antiproliferative activity against human RKO cells assessed as cell growth inhibition by CCK8 assay2021Journal of medicinal chemistry, 06-10, Volume: 64, Issue:11
Discovery of RRx-001, a Myc and CD47 Downregulating Small Molecule with Tumor Targeted Cytotoxicity and Healthy Tissue Cytoprotective Properties in Clinical Development.
AID1220416Binding affinity to monkey hemoglobin assessed as protein bound compound level at 1 uM2012Drug metabolism and disposition: the biological fate of chemicals, Sep, Volume: 40, Issue:9
Preclinical evaluation of the metabolism and disposition of RRx-001, a novel investigative anticancer agent.
AID1220452Ratio of drug level in rat blood to rat plasma at 1 uM after 30 mins2012Drug metabolism and disposition: the biological fate of chemicals, Sep, Volume: 40, Issue:9
Preclinical evaluation of the metabolism and disposition of RRx-001, a novel investigative anticancer agent.
AID1220418Binding affinity to rat hemoglobin assessed as protein bound compound level at 20 uM2012Drug metabolism and disposition: the biological fate of chemicals, Sep, Volume: 40, Issue:9
Preclinical evaluation of the metabolism and disposition of RRx-001, a novel investigative anticancer agent.
AID1220417Binding affinity to human hemoglobin assessed as protein bound compound level at 1 uM2012Drug metabolism and disposition: the biological fate of chemicals, Sep, Volume: 40, Issue:9
Preclinical evaluation of the metabolism and disposition of RRx-001, a novel investigative anticancer agent.
AID1220453Ratio of drug level in dog blood to dog plasma at 1 uM after 30 mins2012Drug metabolism and disposition: the biological fate of chemicals, Sep, Volume: 40, Issue:9
Preclinical evaluation of the metabolism and disposition of RRx-001, a novel investigative anticancer agent.
AID1220397Drug metabolism in human whole blood assessed as (R)-2-amino-3-((2-(3,3-dinitroazetidin-1-yl)-2-oxoethyl)thio)propanoic acid] formation at 20 uM by LC-MS/MS method2012Drug metabolism and disposition: the biological fate of chemicals, Sep, Volume: 40, Issue:9
Preclinical evaluation of the metabolism and disposition of RRx-001, a novel investigative anticancer agent.
AID1814604Antiproliferative activity against human SNB-75 cells assessed as cell growth inhibition by CCK8 assay2021Journal of medicinal chemistry, 06-10, Volume: 64, Issue:11
Discovery of RRx-001, a Myc and CD47 Downregulating Small Molecule with Tumor Targeted Cytotoxicity and Healthy Tissue Cytoprotective Properties in Clinical Development.
AID1220442Drug metabolism assessed as [(S)-2-amino-5-(((R)-1-((carboxymethyl)amino)-3-((2-(3,3-dinitroazetidin-1-yl)-2-oxoethyl)thio)-1-oxopropan-2-yl)amino)-5-oxopentanoic acid] formation after 1 hr in presence of reduced GSH at pH 7.8 by LC-MS/MS method2012Drug metabolism and disposition: the biological fate of chemicals, Sep, Volume: 40, Issue:9
Preclinical evaluation of the metabolism and disposition of RRx-001, a novel investigative anticancer agent.
AID1220394Retention time in rat whole blood in presence of 0.1% formic acid in acetonitrile at 20 uM by LC-MS/MS method2012Drug metabolism and disposition: the biological fate of chemicals, Sep, Volume: 40, Issue:9
Preclinical evaluation of the metabolism and disposition of RRx-001, a novel investigative anticancer agent.
AID1220438Drug level in Wistar Hanover rat blood at 10 mg/kg, iv administered as single dose after 24 hrs2012Drug metabolism and disposition: the biological fate of chemicals, Sep, Volume: 40, Issue:9
Preclinical evaluation of the metabolism and disposition of RRx-001, a novel investigative anticancer agent.
AID1814605Antiproliferative activity against human MCF7 cells assessed as cell growth inhibition by CCK8 assay2021Journal of medicinal chemistry, 06-10, Volume: 64, Issue:11
Discovery of RRx-001, a Myc and CD47 Downregulating Small Molecule with Tumor Targeted Cytotoxicity and Healthy Tissue Cytoprotective Properties in Clinical Development.
AID1220441Stability in pH 7.0 buffer2012Drug metabolism and disposition: the biological fate of chemicals, Sep, Volume: 40, Issue:9
Preclinical evaluation of the metabolism and disposition of RRx-001, a novel investigative anticancer agent.
AID1814601Antiproliferative activity against human U87 cells assessed as cell growth inhibition by CCK8 assay2021Journal of medicinal chemistry, 06-10, Volume: 64, Issue:11
Discovery of RRx-001, a Myc and CD47 Downregulating Small Molecule with Tumor Targeted Cytotoxicity and Healthy Tissue Cytoprotective Properties in Clinical Development.
AID1220398Drug metabolism in rat whole blood assessed as (R)-2-amino-3-((2-(3,3-dinitroazetidin-1-yl)-2-oxoethyl)thio)propanoic acid] formation at 20 uM by LC-MS/MS method2012Drug metabolism and disposition: the biological fate of chemicals, Sep, Volume: 40, Issue:9
Preclinical evaluation of the metabolism and disposition of RRx-001, a novel investigative anticancer agent.
AID1220393Retention time in human whole blood in presence of 0.1% formic acid in acetonitrile at 20 uM by LC-MS/MS method2012Drug metabolism and disposition: the biological fate of chemicals, Sep, Volume: 40, Issue:9
Preclinical evaluation of the metabolism and disposition of RRx-001, a novel investigative anticancer agent.
AID1220407Drug metabolism in human whole blood assessed as [(S)-2-amino-5-(((R)-1-((carboxymethyl)amino)-3-((2-(3-(hydroxyimino)azetidin-1-yl)-2-oxoethyl)thio)-1-oxopropan-2-yl)amino)-5-oxopentanoic acid] formation at 20 uM by LC-MS/MS method2012Drug metabolism and disposition: the biological fate of chemicals, Sep, Volume: 40, Issue:9
Preclinical evaluation of the metabolism and disposition of RRx-001, a novel investigative anticancer agent.
AID1220415Binding affinity to dog hemoglobin assessed as protein bound compound level at 1 uM2012Drug metabolism and disposition: the biological fate of chemicals, Sep, Volume: 40, Issue:9
Preclinical evaluation of the metabolism and disposition of RRx-001, a novel investigative anticancer agent.
AID1220411Binding affinity to human hemoglobin assessed as alkylation on Hb beta chain Cys-93 locus at 0.53 to 5.5 mM by LC-MS/MS method2012Drug metabolism and disposition: the biological fate of chemicals, Sep, Volume: 40, Issue:9
Preclinical evaluation of the metabolism and disposition of RRx-001, a novel investigative anticancer agent.
AID1220413Ratio of drug level in human blood to human plasma at 20 uM after 30 mins2012Drug metabolism and disposition: the biological fate of chemicals, Sep, Volume: 40, Issue:9
Preclinical evaluation of the metabolism and disposition of RRx-001, a novel investigative anticancer agent.
AID1220439Drug level in Wistar Hanover rat blood at 10 mg/kg, iv administered as single dose after 168 hrs2012Drug metabolism and disposition: the biological fate of chemicals, Sep, Volume: 40, Issue:9
Preclinical evaluation of the metabolism and disposition of RRx-001, a novel investigative anticancer agent.
AID1814600Antiproliferative activity against human M21 cells assessed as cell growth inhibition by CCK8 assay2021Journal of medicinal chemistry, 06-10, Volume: 64, Issue:11
Discovery of RRx-001, a Myc and CD47 Downregulating Small Molecule with Tumor Targeted Cytotoxicity and Healthy Tissue Cytoprotective Properties in Clinical Development.
AID1814598Antiproliferative activity against human UMSCC22B cells assessed as cell growth inhibition by CCK8 assay2021Journal of medicinal chemistry, 06-10, Volume: 64, Issue:11
Discovery of RRx-001, a Myc and CD47 Downregulating Small Molecule with Tumor Targeted Cytotoxicity and Healthy Tissue Cytoprotective Properties in Clinical Development.
AID1814608Antiproliferative activity against human A549 cells assessed as cell growth inhibition by CCK8 assay2021Journal of medicinal chemistry, 06-10, Volume: 64, Issue:11
Discovery of RRx-001, a Myc and CD47 Downregulating Small Molecule with Tumor Targeted Cytotoxicity and Healthy Tissue Cytoprotective Properties in Clinical Development.
AID1220422AUC (0 to t) in Wistar Hanover rat blood at 10 mg/kg, iv administered as single dose2012Drug metabolism and disposition: the biological fate of chemicals, Sep, Volume: 40, Issue:9
Preclinical evaluation of the metabolism and disposition of RRx-001, a novel investigative anticancer agent.
AID1220408Drug metabolism in rat whole blood assessed as [(S)-2-amino-5-(((R)-1-((carboxymethyl)amino)-3-((2-(3-(hydroxyimino)azetidin-1-yl)-2-oxoethyl)thio)-1-oxopropan-2-yl)amino)-5-oxopentanoic acid] formation at 20 uM by LC-MS/MS method2012Drug metabolism and disposition: the biological fate of chemicals, Sep, Volume: 40, Issue:9
Preclinical evaluation of the metabolism and disposition of RRx-001, a novel investigative anticancer agent.
AID1220402Drug metabolism in rat whole blood assessed as [(R)-2-amino-3-((2-(3-nitroazetidin-1-yl)-2-oxoethyl)thio)propanoic acid] formation at 20 uM by LC-MS/MS method2012Drug metabolism and disposition: the biological fate of chemicals, Sep, Volume: 40, Issue:9
Preclinical evaluation of the metabolism and disposition of RRx-001, a novel investigative anticancer agent.
AID1220456Ratio of drug level in rat blood to rat plasma at 20 uM after 30 mins2012Drug metabolism and disposition: the biological fate of chemicals, Sep, Volume: 40, Issue:9
Preclinical evaluation of the metabolism and disposition of RRx-001, a novel investigative anticancer agent.
AID1220428Drug excretion in Wistar Hanover rat feces at 10 mg/kg, iv administered as single dose measured on day 22012Drug metabolism and disposition: the biological fate of chemicals, Sep, Volume: 40, Issue:9
Preclinical evaluation of the metabolism and disposition of RRx-001, a novel investigative anticancer agent.
AID1220454Ratio of drug level in monkey blood to monkey plasma at 1 uM after 30 mins2012Drug metabolism and disposition: the biological fate of chemicals, Sep, Volume: 40, Issue:9
Preclinical evaluation of the metabolism and disposition of RRx-001, a novel investigative anticancer agent.
AID1220432Ratio of drug level in blood to plasma in Wistar Hanover rat at 10 mg/kg, iv administered as single dose after 168 hrs2012Drug metabolism and disposition: the biological fate of chemicals, Sep, Volume: 40, Issue:9
Preclinical evaluation of the metabolism and disposition of RRx-001, a novel investigative anticancer agent.
AID1814596Antitumor activity against mouse SCC-7 cells implanted in C3H mouse assessed as tumor growth time delay at 12 mg/kg, ip treated every other day 3 times in total2021Journal of medicinal chemistry, 06-10, Volume: 64, Issue:11
Discovery of RRx-001, a Myc and CD47 Downregulating Small Molecule with Tumor Targeted Cytotoxicity and Healthy Tissue Cytoprotective Properties in Clinical Development.
AID1220396Drug metabolism in rat whole blood assessed as [(S)-2-amino-5-(((R)-1-((carboxymethyl)amino)-3-((2-(3,3-dinitroazetidin-1-yl)-2-oxoethyl)thio)-1-oxopropan-2-yl)amino)-5-oxopentanoic acid] formation at 20 uM by LC-MS/MS method2012Drug metabolism and disposition: the biological fate of chemicals, Sep, Volume: 40, Issue:9
Preclinical evaluation of the metabolism and disposition of RRx-001, a novel investigative anticancer agent.
AID1814606Antiproliferative activity against human A498 cells assessed as cell growth inhibition by CCK8 assay2021Journal of medicinal chemistry, 06-10, Volume: 64, Issue:11
Discovery of RRx-001, a Myc and CD47 Downregulating Small Molecule with Tumor Targeted Cytotoxicity and Healthy Tissue Cytoprotective Properties in Clinical Development.
AID1220455Ratio of drug level in human blood to human plasma at 1 uM after 30 mins2012Drug metabolism and disposition: the biological fate of chemicals, Sep, Volume: 40, Issue:9
Preclinical evaluation of the metabolism and disposition of RRx-001, a novel investigative anticancer agent.
AID1814609Terminal half life in human plasma2021Journal of medicinal chemistry, 06-10, Volume: 64, Issue:11
Discovery of RRx-001, a Myc and CD47 Downregulating Small Molecule with Tumor Targeted Cytotoxicity and Healthy Tissue Cytoprotective Properties in Clinical Development.
AID1220426AUC (0 to infinity) in Wistar Hanover rat plasma at 10 mg/kg, iv administered as single dose2012Drug metabolism and disposition: the biological fate of chemicals, Sep, Volume: 40, Issue:9
Preclinical evaluation of the metabolism and disposition of RRx-001, a novel investigative anticancer agent.
AID1220436Drug level in Wistar Hanover rat bile at 10 mg/kg, iv administered as single dose after 24 hrs2012Drug metabolism and disposition: the biological fate of chemicals, Sep, Volume: 40, Issue:9
Preclinical evaluation of the metabolism and disposition of RRx-001, a novel investigative anticancer agent.
AID1220445Drug metabolism assessed as [(S)-2-amino-5-(((R)-1-((carboxymethyl)amino)-3-((2-(3-nitroazetidin-1-yl)-2-oxoethyl)thio)-1-oxopropan-2-yl)amino)-5-oxopentanoic acid] formation after 1 hr in presence of excess reduced GSH at pH 7.8 by LC-MS/MS method2012Drug metabolism and disposition: the biological fate of chemicals, Sep, Volume: 40, Issue:9
Preclinical evaluation of the metabolism and disposition of RRx-001, a novel investigative anticancer agent.
AID1220423Half life in Wistar Hanover rat plasma at 10 mg/kg, iv administered as single dose2012Drug metabolism and disposition: the biological fate of chemicals, Sep, Volume: 40, Issue:9
Preclinical evaluation of the metabolism and disposition of RRx-001, a novel investigative anticancer agent.
AID1220444Drug metabolism assessed as (R)-2-amino-3-((2-(3,3-dinitroazetidin-1-yl)-2-oxoethyl)thio)propanoic acid] formation after 1 hr in presence of cysteine at pH 7.8 by LC-MS/MS method2012Drug metabolism and disposition: the biological fate of chemicals, Sep, Volume: 40, Issue:9
Preclinical evaluation of the metabolism and disposition of RRx-001, a novel investigative anticancer agent.
AID1347411qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Mechanism Interrogation Plate v5.0 (MIPE) Libary2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (45)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's31 (68.89)24.3611
2020's14 (31.11)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 33.85

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index33.85 (24.57)
Research Supply Index3.93 (2.92)
Research Growth Index4.61 (4.65)
Search Engine Demand Index43.69 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (33.85)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials5 (11.11%)5.53%
Reviews9 (20.00%)6.00%
Case Studies3 (6.67%)4.05%
Observational0 (0.00%)0.25%
Other28 (62.22%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
SubstanceRelationship StrengthStudiesTrialsClassesRoles
nitrites
Nitrites: Salts of nitrous acid or compounds containing the group NO2-. The inorganic nitrites of the type MNO2 (where M=metal) are all insoluble, except the alkali nitrites. The organic nitrites may be isomeric, but not identical with the corresponding nitro compounds. (Grant & Hackh's Chemical Dictionary, 5th ed)		2.2110monovalent inorganic anion;
nitrogen oxoanion;
reactive nitrogen species		human metabolite
valproic acid
Valproic Acid: A fatty acid with anticonvulsant and anti-manic properties that is used in the treatment of EPILEPSY and BIPOLAR DISORDER. The mechanisms of its therapeutic actions are not well understood. It may act by increasing GAMMA-AMINOBUTYRIC ACID levels in the brain or by altering the properties of VOLTAGE-GATED SODIUM CHANNELS.. valproic acid : A branched-chain saturated fatty acid that comprises of a propyl substituent on a pentanoic acid stem.		3.2310branched-chain fatty acid;
branched-chain saturated fatty acid		anticonvulsant;
antimanic drug;
EC 3.5.1.98 (histone deacetylase) inhibitor;
GABA agent;
neuroprotective agent;
psychotropic drug;
teratogenic agent
hydralazine
Hydralazine: A direct-acting vasodilator that is used as an antihypertensive agent.. hydralazine : The 1-hydrazino derivative of phthalazine; a direct-acting vasodilator that is used as an antihypertensive agent.		3.2310azaarene;
hydrazines;
ortho-fused heteroarene;
phthalazines		antihypertensive agent;
vasodilator agent
entinostat
[no description available]		4.1320benzamides;
carbamate ester;
primary amino compound;
pyridines;
substituted aniline		antineoplastic agent;
apoptosis inducer;
EC 3.5.1.98 (histone deacetylase) inhibitor
vorinostat
Vorinostat: A hydroxamic acid and anilide derivative that acts as a HISTONE DEACETYLASE inhibitor. It is used in the treatment of CUTANEOUS T-CELL LYMPHOMA and SEZARY SYNDROME.. vorinostat : A dicarboxylic acid diamide comprising suberic (octanedioic) acid coupled to aniline and hydroxylamine. A histone deacetylase inhibitor, it is marketed under the name Zolinza for the treatment of cutaneous T cell lymphoma (CTCL).		3.1910dicarboxylic acid diamide;
hydroxamic acid		antineoplastic agent;
apoptosis inducer;
EC 3.5.1.98 (histone deacetylase) inhibitor
temozolomide
[no description available]		7.3110imidazotetrazine;
monocarboxylic acid amide;
triazene derivative		alkylating agent;
antineoplastic agent;
prodrug
thalidomide
Thalidomide: A piperidinyl isoindole originally introduced as a non-barbiturate hypnotic, but withdrawn from the market due to teratogenic effects. It has been reintroduced and used for a number of immunological and inflammatory disorders. Thalidomide displays immunosuppressive and anti-angiogenic activity. It inhibits release of TUMOR NECROSIS FACTOR-ALPHA from monocytes, and modulates other cytokine action.. thalidomide : A racemate comprising equimolar amounts of R- and S-thalidomide.. 2-(2,6-dioxopiperidin-3-yl)-1H-isoindole-1,3(2H)-dione : A dicarboximide that is isoindole-1,3(2H)-dione in which the hydrogen attached to the nitrogen is substituted by a 2,6-dioxopiperidin-3-yl group.		3.7120phthalimides;
piperidones
thiophenes
Thiophenes: A monocyclic heteroarene furan in which the oxygen atom is replaced by a sulfur.. thiophenes : Compounds containing at least one thiophene ring.		2.2110mancude organic heteromonocyclic parent;
monocyclic heteroarene;
thiophenes;
volatile organic compound		non-polar solvent
azacitidine
Azacitidine: A pyrimidine analogue that inhibits DNA methyltransferase, impairing DNA methylation. It is also an antimetabolite of cytidine, incorporated primarily into RNA. Azacytidine has been used as an antineoplastic agent.. 5-azacytidine : An N-glycosyl-1,3,5-triazine that is 4-amino-1,3,5-triazin-2(1H)-one substituted by a beta-D-ribofuranosyl residue via an N-glycosidic linkage. An antineoplastic agent, it is used in the treatment of myeloid leukaemia.		4.4230N-glycosyl-1,3,5-triazine;
nucleoside analogue		antineoplastic agent
azomycin
azomycin: RN given refers to parent cpd with specified locant; structure		2.1310C-nitro compound;
imidazoles		antitubercular agent
nitroxoline
nitroxoline: structure in Merck Index, 9th ed, #6475; RN given refers to parent cpd. nitroxoline : A monohydroxyquinoline in which the hydroxy group is positioned at C-8 with a nitro group trans to it at C-5.		3.5110C-nitro compound;
monohydroxyquinoline		antifungal agent;
antiinfective agent;
antimicrobial agent;
renal agent
camptothecin
NSC 100880: carboxylate (opened lactone) form of camptothecin; RN refers to (S)-isomer; structure given in first source		3.511delta-lactone;
pyranoindolizinoquinoline;
quinoline alkaloid;
tertiary alcohol		antineoplastic agent;
EC 5.99.1.2 (DNA topoisomerase) inhibitor;
genotoxin;
plant metabolite
etoposide
[no description available]		9.8721beta-D-glucoside;
furonaphthodioxole;
organic heterotetracyclic compound		antineoplastic agent;
DNA synthesis inhibitor
ng-nitroarginine methyl ester
NG-Nitroarginine Methyl Ester: A non-selective inhibitor of nitric oxide synthase. It has been used experimentally to induce hypertension.		2.2110alpha-amino acid ester;
L-arginine derivative;
methyl ester;
N-nitro compound		EC 1.14.13.39 (nitric oxide synthase) inhibitor
pimonidazole
pimonidazole: structure given in first source		2.1310
irinotecan
[no description available]		8.9721carbamate ester;
delta-lactone;
N-acylpiperidine;
pyranoindolizinoquinoline;
ring assembly;
tertiary alcohol;
tertiary amino compound		antineoplastic agent;
apoptosis inducer;
EC 5.99.1.2 (DNA topoisomerase) inhibitor;
prodrug
plerixafor
plerixafor: a bicyclam derivate, highly potent & selective inhibitor of HIV-1 & HIV-2. plerixafor : An azamacrocycle consisting of two cyclam rings connected by a 1,4-phenylenebis(methylene) linker. It is a CXCR4 chemokine receptor antagonist and a hematopoietic stem cell mobilizer. It is used in combination with grulocyte-colony stimulating factor (G-CSF) to mobilize hematopoietic stem cells to the perpheral blood for collection and subsequent autologous transplantation in patients with non-Hodgkin's lymphoma and multiple myeloma.		3.5110azacycloalkane;
azamacrocycle;
benzenes;
crown amine;
secondary amino compound;
tertiary amino compound		anti-HIV agent;
antineoplastic agent;
C-X-C chemokine receptor type 4 antagonist;
immunological adjuvant
artemether
Artemether: An artemisinin derivative that is used in the treatment of MALARIA.. artemether : An artemisinin derivative that is artemisinin in which the lactone has been converted to the corresponding lactol methyl ether. It is used in combination with lumefantrine as an antimalarial for the treatment of multi-drug resistant strains of falciparum malaria.		2.1110artemisinin derivative;
cyclic acetal;
organic peroxide;
semisynthetic derivative;
sesquiterpenoid		antimalarial
bosentan anhydrous
Bosentan: A sulfonamide and pyrimidine derivative that acts as a dual endothelin receptor antagonist used to manage PULMONARY HYPERTENSION and SYSTEMIC SCLEROSIS.		2.2510primary alcohol;
pyrimidines;
sulfonamide		antihypertensive agent;
endothelin receptor antagonist
pomalidomide
3-aminophthalimidoglutarimide: structure in first source		3.7120aromatic amine;
dicarboximide;
isoindoles;
piperidones		angiogenesis inhibitor;
antineoplastic agent;
immunomodulator
lenalidomide
[no description available]		3.5110aromatic amine;
dicarboximide;
isoindoles;
piperidones		angiogenesis inhibitor;
antineoplastic agent;
immunomodulator
bortezomib
[no description available]		3.7120amino acid amide;
L-phenylalanine derivative;
pyrazines		antineoplastic agent;
antiprotozoal drug;
protease inhibitor;
proteasome inhibitor
gant 61
GANT 61: a sonic hedgehog pathway inhibitor and Gli inhibitor; structure in first source. GANT61 : An aminal that is hexahydropyrimidine which is substituted on each nitrogen by a 2-(dimethylamino)benzyl group, and at the aminal carbon by a pyridin-4-yl group. A Hedgehog signaling pathway and Gli protein inhibitor.		3.5110aminal;
dialkylarylamine;
pyridines;
substituted aniline;
tertiary amino compound		antineoplastic agent;
apoptosis inducer;
glioma-associated oncogene inhibitor;
Hedgehog signaling pathway inhibitor
carboplatin
[no description available]		4.921
decitabine
[no description available]		3.19102'-deoxyribonucleoside
nadp
[no description available]		2.1310
p5091
P5091: inhibits ubiquitin-specific protease 7; structure in first source		3.7820
cysteine
Cysteine: A thiol-containing non-essential amino acid that is oxidized to form CYSTINE.. L-cysteinium : The L-enantiomer of cysteinium.. cysteine : A sulfur-containing amino acid that is propanoic acid with an amino group at position 2 and a sulfanyl group at position 3.		2.5420cysteiniumfundamental metabolite
panobinostat
Panobinostat: An indole and hydroxamic acid derivative that acts as a HISTONE DEACETYLASE inhibitor. It is used as an antineoplastic agent in combination with BORTEZOMIB and DEXAMETHASONE for the treatment of MULTIPLE MYELOMA.. panobinostat : A hydroxamic acid obtained by formal condensation of the carboxy group of (2E)-3-[4-({[2-(2-methylindol-3-yl)ethyl]amino}methyl)phenyl]prop-2-enoic acid with the amino group of hydroxylamine. A histone deacetylase inhibitor used (as its lactate salt) in combination with bortezomib and dexamethasone for the treatment of multiple myeloma.		3.5110cinnamamides;
hydroxamic acid;
methylindole;
secondary amino compound		angiogenesis modulating agent;
antineoplastic agent;
EC 3.5.1.98 (histone deacetylase) inhibitor
regorafenib
[no description available]		3.511(trifluoromethyl)benzenes;
aromatic ether;
monochlorobenzenes;
monofluorobenzenes;
phenylureas;
pyridinecarboxamide		antineoplastic agent;
hepatotoxic agent;
tyrosine kinase inhibitor
epoxomicin
[no description available]		3.5110morpholines;
tripeptide		proteasome inhibitor
carfilzomib
[no description available]		3.5110epoxide;
morpholines;
tetrapeptide		antineoplastic agent;
proteasome inhibitor
pevonedistat
pevonedistat: a potent and selective inhibitor of NAE (NEDD8-activating enzyme). pevonedistat : A pyrrolopyrimidine that is 7H-pyrrolo[2,3-d]pyrimidine which is substituted by a (1S)-2,3-dihydro-1H-inden-1-ylnitrilo group at position 4 and by a (1S,3S,4S)-3-hydroxy-4-[(sulfamoyloxy)methyl]cyclopentyl group at position 7. It is a potent and selective NEDD8-activating enzyme inhibitor with an IC50 of 4.7 nM, and currently under clinical investigation for the treatment of acute myeloid leukemia (AML) and myelodysplastic syndromes.		3.5110cyclopentanols;
indanes;
pyrrolopyrimidine;
secondary amino compound;
sulfamidate		antineoplastic agent;
apoptosis inducer
sodium nitrite
Sodium Nitrite: Nitrous acid sodium salt. Used in many industrial processes, in meat curing, coloring, and preserving, and as a reagent in ANALYTICAL CHEMISTRY TECHNIQUES. It is used therapeutically as an antidote in cyanide poisoning. The compound is toxic and mutagenic and will react in vivo with secondary or tertiary amines thereby producing highly carcinogenic nitrosamines.. sodium nitrite : An inorganic sodium salt having nitrite as the counterion. Used as a food preservative and antidote to cyanide poisoning.		2.1510inorganic sodium salt;
nitrite salt		antidote to cyanide poisoning;
antihypertensive agent;
antimicrobial food preservative;
food antioxidant;
poison
mk-1775
adavosertib: a Wee1 kinase inhibitor; structure in first source		3.5110piperazines
ixazomib
ixazomib: a proteasome inhibitor with antineoplastic activity; MLN2238 is the biologically active form of MLN9708; structure in first source. ixazomib : A glycine derivative that is the amide obtained by formal condensation of the carboxy group of N-(2,5-dichlorobenzoyl)glycine with the amino group of [(1R)-1-amino-3-methylbutyl]boronic acid. The active metabolite of ixazomib citrate, it is used in combination therapy for treatment of multiple myeloma.		3.5110benzamides;
boronic acids;
dichlorobenzene;
glycine derivative		antineoplastic agent;
apoptosis inducer;
drug metabolite;
orphan drug;
proteasome inhibitor
arry 520
filanesib: a kinesin spindle protein inhibitor		3.5110
abt-199
venetoclax: A BCL-2 inhibitor with antineoplastic activity that is used in the treatment of CHRONIC LYMPHOCYTIC LEUKEMIA associated with chromosome 17p deletion; structure in first source.. venetoclax : A member of the class of pyrrolopyridines that is a potent inhibitor of the antiapoptotic protein B-cell lymphoma 2. It is used for treamtment of chronic lymphocytic leukemia with 17p deletion.		3.5110aromatic ether;
C-nitro compound;
monochlorobenzenes;
N-alkylpiperazine;
N-arylpiperazine;
N-sulfonylcarboxamide;
oxanes;
pyrrolopyridine		antineoplastic agent;
apoptosis inducer;
B-cell lymphoma 2 inhibitor
acy-1215
ricolinostat: an HDAC6 inhibitor; structure in first source		3.5110pyrimidinecarboxylic acid
selinexor
selinexor: inhibits karyopherin XPO1		3.5110
cyclic gmp
Cyclic GMP: Guanosine cyclic 3',5'-(hydrogen phosphate). A guanine nucleotide containing one phosphate group which is esterified to the sugar moiety in both the 3'- and 5'-positions. It is a cellular regulatory agent and has been described as a second messenger. Its levels increase in response to a variety of hormones, including acetylcholine, insulin, and oxytocin and it has been found to activate specific protein kinases. (From Merck Index, 11th ed). 3',5'-cyclic GMP : A 3',5'-cyclic purine nucleotide in which the purine nucleobase is specified as guanidine.		2.17103',5'-cyclic purine nucleotide;
guanyl ribonucleotide		Escherichia coli metabolite;
human metabolite;
mouse metabolite;
plant metabolite;
Saccharomyces cerevisiae metabolite
ConditionIndicatedRelationship StrengthStudiesTrials
Benign Neoplasms
[description not available]		09.47162
Neoplasms
New abnormal growth of tissue. Malignant neoplasms show a greater degree of anaplasia and have the properties of invasion and metastasis, compared to benign neoplasms.		09.47162
Kahler Disease
[description not available]		03.5320
Multiple Myeloma
A malignancy of mature PLASMA CELLS engaging in monoclonal immunoglobulin production. It is characterized by hyperglobulinemia, excess Bence-Jones proteins (free monoclonal IMMUNOGLOBULIN LIGHT CHAINS) in the urine, skeletal destruction, bone pain, and fractures. Other features include ANEMIA; HYPERCALCEMIA; and RENAL INSUFFICIENCY.		08.5320
Innate Inflammatory Response
[description not available]		04.0230
Periphlebitis
Periphlebitis is inflammation of the outer coat of a vein or of tissues surrounding the vein.		02.4110
Inflammation
A pathological process characterized by injury or destruction of tissues caused by a variety of cytologic and chemical reactions. It is usually manifested by typical signs of pain, heat, redness, swelling, and loss of function.		04.0230
Phlebitis
Inflammation of a vein, often a vein in the leg. Phlebitis associated with a blood clot is called (THROMBOPHLEBITIS).		02.4110
Cancer of Head
[description not available]		04.9111
Mucositis, Oral
[description not available]		04.9111
Head and Neck Neoplasms
Soft tissue tumors or cancer arising from the mucosal surfaces of the LIP; oral cavity; PHARYNX; LARYNX; and cervical esophagus. Other sites included are the NOSE and PARANASAL SINUSES; SALIVARY GLANDS; THYROID GLAND and PARATHYROID GLANDS; and MELANOMA and non-melanoma skin cancers of the head and neck. (from Holland et al., Cancer Medicine, 4th ed, p1651)		04.9111
Stomatitis
INFLAMMATION of the soft tissues of the MOUTH, such as MUCOSA; PALATE; GINGIVA; and LIP.		16.9111
Cancer, Second Primary
[description not available]		03.9911
Cancer of Lung
[description not available]		06.3241
Lung Neoplasms
Tumors or cancer of the LUNG.		06.3241
Carcinoma, Small Cell Lung
[description not available]		04.5111
Small Cell Lung Carcinoma
A form of highly malignant lung cancer that is composed of small ovoid cells (SMALL CELL CARCINOMA).		04.5111
2019 Novel Coronavirus Disease
[description not available]		02.2510
Thrombopenia
[description not available]		02.3110
Anemia
A reduction in the number of circulating ERYTHROCYTES or in the quantity of HEMOGLOBIN.		07.3110
Thrombocytopenia
A subnormal level of BLOOD PLATELETS.		07.3110
Allergic Encephalomyelitis
[description not available]		02.3110
Colitis
Inflammation of the COLON section of the large intestine (INTESTINE, LARGE), usually with symptoms such as DIARRHEA (often with blood and mucus), ABDOMINAL PAIN, and FEVER.		02.3110
Benign Neoplasms, Brain
[description not available]		02.5920
Glial Cell Tumors
[description not available]		02.3110
Brain Neoplasms
Neoplasms of the intracranial components of the central nervous system, including the cerebral hemispheres, basal ganglia, hypothalamus, thalamus, brain stem, and cerebellum. Brain neoplasms are subdivided into primary (originating from brain tissue) and secondary (i.e., metastatic) forms. Primary neoplasms are subdivided into benign and malignant forms. In general, brain tumors may also be classified by age of onset, histologic type, or presenting location in the brain.		14.5920
Glioma
Benign and malignant central nervous system neoplasms derived from glial cells (i.e., astrocytes, oligodendrocytes, and ependymocytes). Astrocytes may give rise to astrocytomas (ASTROCYTOMA) or glioblastoma multiforme (see GLIOBLASTOMA). Oligodendrocytes give rise to oligodendrogliomas (OLIGODENDROGLIOMA) and ependymocytes may undergo transformation to become EPENDYMOMA; CHOROID PLEXUS NEOPLASMS; or colloid cysts of the third ventricle. (From Escourolle et al., Manual of Basic Neuropathology, 2nd ed, p21)		07.3110
Disease Models, Animal
Naturally-occurring or experimentally-induced animal diseases with pathological processes analogous to human diseases.		02.8230
Injury, Ischemia-Reperfusion
[description not available]		02.1510
Reperfusion Injury
Adverse functional, metabolic, or structural changes in tissues that result from the restoration of blood flow to the tissue (REPERFUSION) following ISCHEMIA.		07.1510
Androgen-Independent Prostatic Cancer
[description not available]		02.1710
Carcinoma, Neuroendocrine
A group of carcinomas which share a characteristic morphology, often being composed of clusters and trabecular sheets of round blue cells, granular chromatin, and an attenuated rim of poorly demarcated cytoplasm. Neuroendocrine tumors include carcinoids, small (oat) cell carcinomas, medullary carcinoma of the thyroid, Merkel cell tumor, cutaneous neuroendocrine carcinoma, pancreatic islet cell tumors, and pheochromocytoma. Neurosecretory granules are found within the tumor cells. (Segen, Dictionary of Modern Medicine, 1992)		02.1710
Prostatic Neoplasms, Castration-Resistant
Tumors or cancer of the PROSTATE which can grow in the presence of low or residual amount of androgen hormones such as TESTOSTERONE.		02.1710
Hypercoagulability
[description not available]		02.1710
Thrombophilia
A disorder of HEMOSTASIS in which there is a tendency for the occurrence of THROMBOSIS.		02.1710
Bladder Cancer
[description not available]		02.2110
Urinary Bladder Neoplasms
Tumors or cancer of the URINARY BLADDER.		02.2110
Parasitemia
The presence of parasites (especially malarial parasites) in the blood. (Dorland, 27th ed)		02.1110
Cerebral Malaria
[description not available]		07.1110
Anoxemia
[description not available]		03.4420
Hypoxia
Sub-optimal OXYGEN levels in the ambient air of living organisms.		08.4420
Adverse Drug Event
[description not available]		04.4111
Drug-Related Side Effects and Adverse Reactions
Disorders that result from the intended use of PHARMACEUTICAL PREPARATIONS. Included in this heading are a broad variety of chemically-induced adverse conditions due to toxicity, DRUG INTERACTIONS, and metabolic effects of pharmaceuticals.		04.4111
Carcinoma, Epidermoid
[description not available]		02.4920
Carcinoma, Squamous Cell
A carcinoma derived from stratified SQUAMOUS EPITHELIAL CELLS. It may also occur in sites where glandular or columnar epithelium is normally present. (From Stedman, 25th ed)		02.4920
Malignant Melanoma
[description not available]		02.1310
Melanoma
A malignant neoplasm derived from cells that are capable of forming melanin, which may occur in the skin of any part of the body, in the eye, or, rarely, in the mucous membranes of the genitalia, anus, oral cavity, or other sites. It occurs mostly in adults and may originate de novo or from a pigmented nevus or malignant lentigo. Melanomas frequently metastasize widely, and the regional lymph nodes, liver, lungs, and brain are likely to be involved. The incidence of malignant skin melanomas is rising rapidly in all parts of the world. (Stedman, 25th ed; from Rook et al., Textbook of Dermatology, 4th ed, p2445)		07.1310
Disease Exacerbation
[description not available]		03.0410
Carcinoma, Non-Small Cell Lung
[description not available]		03.4520
Local Neoplasm Recurrence
[description not available]		03.0410
Carcinoma, Non-Small-Cell Lung
A heterogeneous aggregate of at least three distinct histological types of lung cancer, including SQUAMOUS CELL CARCINOMA; ADENOCARCINOMA; and LARGE CELL CARCINOMA. They are dealt with collectively because of their shared treatment strategy.		03.4520
Experimental Neoplasms
[description not available]		02.1310
Cancer of Colon
[description not available]		02.1510
Colonic Neoplasms
Tumors or cancer of the COLON.		02.1510
Metastase
[description not available]		03.511
Colorectal Cancer
[description not available]		03.511
Neoplasm Metastasis
The transfer of a neoplasm from one organ or part of the body to another remote from the primary site.		03.511
Colorectal Neoplasms
Tumors or cancer of the COLON or the RECTUM or both. Risk factors for colorectal cancer include chronic ULCERATIVE COLITIS; FAMILIAL POLYPOSIS COLI; exposure to ASBESTOS; and irradiation of the CERVIX UTERI.		15.511